Cytokinetics
CYTKApprovedFounded in 1998 and headquartered in South San Francisco, Cytokinetics has established itself as a leader in muscle-directed therapeutics with over 25 years of experience in muscle biology. The company went public in 2004 and has conducted more than 100 clinical trials with tens of thousands of patients. With their first FDA-approved medicine MYQORZO launched in 2025 and multiple Phase 3 programs advancing, Cytokinetics is transitioning from a development-stage company to a commercial-stage specialty biopharmaceutical company focused on improving outcomes for patients with debilitating muscle dysfunction diseases.
CYTK · Stock Price
Historical price data
AI Company Overview
Founded in 1998 and headquartered in South San Francisco, Cytokinetics has established itself as a leader in muscle-directed therapeutics with over 25 years of experience in muscle biology. The company went public in 2004 and has conducted more than 100 clinical trials with tens of thousands of patients. With their first FDA-approved medicine MYQORZO launched in 2025 and multiple Phase 3 programs advancing, Cytokinetics is transitioning from a development-stage company to a commercial-stage specialty biopharmaceutical company focused on improving outcomes for patients with debilitating muscle dysfunction diseases.
Technology Platform
Cytokinetics develops small molecule muscle activators and inhibitors that directly target the sarcomere, the fundamental contractile unit of muscle, enabling precise modulation of muscle function in cardiovascular and neuromuscular diseases.
Pipeline Snapshot
3838 drugs in pipeline, 11 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) + Placebo to match aficamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 |
| Omecamtiv Mecarbil (OM) + Placebo | Heart Failure | Phase 3 |
| Omecamtiv mecarbil | Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 |
| Tirasemtiv + Placebo tablets | Amyotrophic Lateral Sclerosis | Phase 3 |
| Omecamtiv Mecarbil + Placebo + Standard of Care | Heart Failure | Phase 3 |
Funding History
5Total raised: $289M
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
Cytokinetics competes primarily with Bristol Myers Squibb's mavacamten (Camzyos) in the HCM space, representing the main direct competition for their lead product MYQORZO. The company differentiates through their extensive muscle biology expertise, broad clinical development programs, and unique pharmacological profiles of their sarcomere-directed therapeutics across multiple indications.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile